News Category
My MMJ Doctor's new Dispensary Partner Program offers cannabis retailers affiliate commissions on medical card evaluations, providing a new revenue st...
Helus Pharma's HLP003 and HLP004 could transform treatment for major depressive disorder and generalized anxiety disorder, pending late-stage trial re...
The Citizens Commission on Human Rights International has formally opposed FDA approval of psychedelic drugs for mental health treatment, warning of s...
NeuroThera Labs has expanded its U.S. patent portfolio through a collaboration with Clearmind Medicine, covering novel combinations of LSD, ketamine, ...
Helus Pharma presented four posters on its investigational oral deuterated psilocin analog HLP003 at Psych Congress 2026, including 12-month efficacy ...
Optimi Health Corp. plans a Health Canada-authorized Phase 3 clinical trial of MDMA-assisted therapy for PTSD, targeting veterans and frontline worker...
Optimi Health Corp. plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder in the f...
Helus Pharma's CEO participation at the Cantor conference underscores the company's advancing clinical trials for depression and anxiety treatments, s...
Carolindica launched a new line of high-potency CBD, CBG, and minor cannabinoid products in gummies and capsules, offering targeted daytime, nighttime...
Helus Pharma has completed enrollment in its pivotal Phase 3 APPROACH trial evaluating HLP003 for major depressive disorder, with topline results expe...
NuggMD commits 3% of its weekly revenue to NORML, highlighting the importance of continued advocacy after the federal government rescheduled cannabis ...
The Medical Resource Association will host its third annual Science in the City International symposium in Paris in 2026, focusing on cannabinoid ther...
Optimi Health Corp. has shipped naturally derived psilocybin capsules and biomass to the UK for a Phase 2 trial, marking a key step in expanding inter...
Optimi Health Corp. announced progress on its Ibogaine Initiative, securing naturally derived ibogaine and planning GMP-grade production of encapsulat...
Optimi Health Corp. has completed a GMP production run of 5mg psilocybin capsules, using the same formulation prescribed in Australia, with product de...
Optimi Health praises Australia's updated psilocybin and MDMA prescribing rules, which broaden therapy teams and settings, potentially accelerating ad...
Optimi Health Corp. praised Australia’s TGA final recommendations that expand eligible therapy teams and treatment settings for psilocybin and MDMA, p...
NuggMD launches in the UK and integrates Stripe for seamless payments, enhancing access for medical cannabis patients.
Jupiter Neurosciences closed a $2 million registered direct offering to fund its CNS pipeline, including a Phase IIa trial for Parkinson's disease and...
Optimi Health Corp. was featured in a Diamond Equity Research report emphasizing its GMP-certified psychedelic manufacturing, growing traction in Aust...
Indiana legislators may resume discussions on medical cannabis, while state officials express uncertainty about federal action prompting policy change...
A new report released at Cannabis Europa 2026 indicates that Europe's cannabis economy is entering a significant growth phase, driven by expanding med...
A new report from the Global Cannabis Network Collective and Whitney Economics highlights that Europe's cannabis market is undergoing a pivotal transf...
The U.S. House passed an amendment to let VA physicians recommend medical marijuana in legal states, potentially expanding veteran healthcare access a...
The U.S. House passed an amendment that would permit VA physicians to recommend medical cannabis in states where it is legal, potentially expanding tr...
A new preclinical study from UC Riverside explains why regular cannabis users often have lower body weight and lower type 2 diabetes risk, supporting ...
A federally backed study reveals that many older Americans are using cannabis to alleviate symptoms after traditional medical treatments proved ineffe...
A recent federal decision to reclassify medical cannabis is altering the landscape for licensed operators, drawing renewed attention from businesses a...
The potential rescheduling of cannabis in the U.S. could transform scientific research and the cannabis industry, but the pace of change is slow and d...
Silo Pharma announced a strategic initiative to develop ibogaine-based treatments for traumatic brain injury and related conditions, filing a provisio...
Businesses can begin applying for medical cannabis dispensary licenses starting April 29, following a DEA directive aligned with President Trump's ord...
A directive signed by Acting AG Todd Blanche reclassifies FDA-approved marijuana-based medications and state-licensed medical cannabis from Schedule I...
Silo Pharma noted coordinated U.S. federal actions accelerating psychedelic-based therapy development for mental health and substance use disorders, c...
Dr. Sanjay Gupta’s evolving documentary series 'Weed' highlights the intersection of cannabis, medicine, and patient experience, with implications for...
